BTEC:SW:SW-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) USD (USD)

ETF | Others |

Last Closing

USD 6.431

Change

-0.08 (-1.18)%

Market Cap

USD 0.48B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHSRIA:SW UBS ETF (CH) MSCI Switzerland ..

-0.11 (-0.52%)

USD 492,935.36B
XLDX:SW Xtrackers LevDAX Daily Swap UC..

-2.94 (-1.75%)

USD 411,075.38B
CHSRI:SW UBS ETF (CH) - MSCI Switzerlan..

-0.14 (-0.77%)

USD 368,190.74B
XNIF:SW Xtrackers Nifty 50 Swap UCITS ..

+1.10 (+0.45%)

USD 292,109.69B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

-0.12 (-0.53%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

-0.15 (-0.52%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

N/A

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

+9.50 (+0.20%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

-4.20 (-0.28%)

USD 134,034.86B

ETFs Containing BTEC:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.72% 21% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.72% 21% F 24% F
Trailing 12 Months  
Capital Gain 9.04% 42% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.04% 42% F 45% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.46% 42% F 44% F
Dividend Return 1.46% 42% F 43% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 3.13% 75% C 79% B-
Risk Adjusted Return 46.59% 48% F 52% F
Market Capitalization 0.48B 64% D 59% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.